Arcturus Revenue and Competitors

Boston, MA USA

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Arcturus's estimated annual revenue is currently $1.3M per year.(i)
  • Arcturus's estimated revenue per employee is $87,000

Employee Data

  • Arcturus has 15 Employees.(i)
  • Arcturus grew their employee count by 0% last year.

Arcturus's People

NameTitleEmail/Phone
1
Machine Learning EngineerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$75.6M4175%N/AN/A
#2
$38.6M24226%N/AN/A
#3
$277.8M1340-1%$38MN/A
#4
$29M186-35%$78.9MN/A
#5
$763.6M12414%$1.8MN/A
#6
$11.9M82-44%$19.5MN/A
#7
$64.9M358-8%N/AN/A
#8
$64.5M350-46%$130MN/A
#9
$26M16336%N/AN/A
#10
$94.5M51322%$187MN/A
Add Company

What Is Arcturus?

MISSION Here at Arcturus, our vision is that all people, wherever they are, have the right to stay safe. We are an advanced technology company focused on understanding the unknown physical dangers in public safety. We use the power of intuitive technology to streamline business operations, keep people informed, connected, and safe from harm through our platform Orion. As a result, Orion delivers decades of understanding dangerous events, logistical physical risk and personal safety at your fingertips. Making our vision a reality and empowering people to safely make it home. PRODUCT Orion, our easy to use platform, is the future in understanding physical dangers, dangerous events, and public safety complexities that impact businesses and people. Designed by Arcturus, this solution is at your fingertips. A truly modern global platform that is powered by the collective knowledge of those invested in business operations & logistical personnel safety.

keywords:N/A

N/A

Total Funding

15

Number of Employees

$1.3M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Arcturus News

2022-04-17 - Arcturus' self-amplifying COVID-19 mRNA vaccine meets ...

Arcturus Therapeutics Holdings Inc. has reported topline data from an ongoing Phase 1/2/3 trial evaluating ARCT-154, its self-amplifying...

2022-04-17 - Arcturus slides on PhIII Covid-19 vaccine data, signifying the ...

The latest example is Arcturus Therapeutics, which touted results from a “Phase I/II/III study” early Wednesday saying its self-amplifying...

2022-04-17 - Arcturus' stock sinks after self-amplifying COVID-19 mRNA ...

The company focuses on neuroscience and immuno-oncology medicines, and its current pipeline includes therapeutics for patients with...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.4M157%N/A
#2
$2M15-12%N/A
#3
$1.5M150%$78M
#4
$1M150%$50M
#5
$1.6M15N/AN/A